B+
Bull case
25%
Probability
Target price
$35.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
LEGN
Legend BiotechANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$25.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$13.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
+0.3
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+100.0
Score
AI commentary
Official Legend investor-relations releases verify the constructive operating and clinical tone: Q2 delivered 50% CARVYKTI net-trade-sales growth, positive operating income and adjusted net income, while the September IMS program creates a specific near-term evidence checkpoint. However, verified analyst revisions, options data, short interest, sufficient social coverage, and a clean post-earnings market-reaction attribution remain unavailable; the sharp gap between the anchor and a target lacking a documented analyst count should not be treated as positive evidence. Confidence therefore remains moderate and monitoring-oriented.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-25eventSeptember IMS data will test CARVYKTI durability and real-world safetyMedium impact
Legend scheduled updated CARTITUDE-2 Cohort A follow-up, including at least five-year remission and survival data, for September 25, alongside real-world outcomes and post-authorization safety findings during the September 23-26 IMS meeting. Durable earlier-line efficacy would support adoption, while the safety evidence is particularly important given CARVYKTI's boxed warnings. [#IR-2026-09-10]
2026-11-15catalystThe next earnings update must confirm that the first profitable quarter is repeatableHigh impact
Q2 CARVYKTI net trade sales rose 50% year over year to approximately $657 million, availability expanded to 348 sites in 19 markets, operating income reached $57.7 million, and adjusted net income reached $63.1 million. Management said it expected adjusted-net-income profitability through the second half of 2026, making the next quarterly report an important operating-leverage test. [#IR-2026-08-11] [#PR-EARNINGS-2026-08-12]
2027-06-30catalystLB2501 follow-up could validate or weaken the in vivo CAR-T platform thesisHigh impact
Initial Phase 1 LB2501 results showed a 100% objective response rate and 83.3% complete-response rate among six patients at the higher dose, without lymphodepletion; however, follow-up was short and the sample was very small. Additional patients and longer durability and safety follow-up are required before assigning substantial platform value. [#IR-2026-06-14] [#IR-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology